← board
ACET
Adicet Therapeuticsdistress 5/10 · elevated risk$8.35-3%today-50% from 52w high
Oncology 2
Lead: systemic sclerosis · target CD20
Revenue
pre-revenue
Liquidity
$133M
Runway
1.4 yrs
Shares 1y
-89%
Price & events
-0.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
+1.6%
1W
+2.5%
1M
+5.7%
3M
-1.1%
6M
-36.0%
1Y
-63.8%
2Y
-93.6%
5Y
-96.1%
All
Overview
- Market Cap
- $78.06M
- Volume
- 23.64K
- 52 Week Range
- $6.11 – $16.64
- Total Shares
- 9.35M
- Float Shares
- 7.43M
- Short %
- 5.43%
- % Held by Insiders
- 1.08%
- % Held by Institutions
- 63.33%
- RVOL
- 0.28x
- Beta
- 1.59
Pipeline stages · 1 programs
ADI-270, Fludarabine, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 1/2 | ADI-270, Fludarabine, Cyclophosphamidefast track | Clear Cell Renal Cell Carcinoma | 60 | active not recruiting |
| 2025-02-03 | Phase 1 | ADI-001, Fludarabine, Cyclophosphamidefast track | Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin | 34 | terminated |
Catalyst news & presentations · 15
- second half of 2026Guided 55%readoutPhase 1ADI-001 · Clinical update in SSc.SEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondaryPhase 1ADI-212 · Initiate enrollment for ADI-212.SEC 8-K
- first half of 2026readoutPhase 1ADI-001 · Clinical update in SSc.SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)ADI-212 · Plan to submit regulatory filing.SEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 2prulacabtagene leucel · Plan to request FDA meeting to inform Phase 2 pivotal trial design.SEC 8-K
- first half of 2026readoutPhase 1prulacabtagene leucel · Next clinical update expected.SEC 8-K
- first quarter of 2026regulatory submissionFiled (NDA/BLA)ADI-212 · Submit regulatory filing for ADI-212.SEC 8-K
- second half of 2025trial initiationsecondaryPhase 1ADI-001 · Expected initiation of patient enrollment for anti-neutrophil cytoplasmic autoantibody associated vasculitis.SEC 8-K
- 2025-07-23trial discontinuedADI-270 · Development discontinued for ccRCC, enrollment closed.SEC 8-K
- first half of 2025readoutPhase 1ADI-270 · Anticipated reporting of preliminary results from the Phase 1 ccRCC trial.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 1ADI-001 · Initiate enrollment for IIM and SPS patients as part of ongoing Phase 1 trial.SEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 1ADI-001 · Initiate enrollment for SLE, SSc, and AAV armsSEC 8-K
- September 19, 2024conferencedata presentationsecondaryPhase 1ADI-001 · Translational data at 9th Annual CAR-TCR SummitSEC 8-K
- 2024-09-10trial discontinuedADI-001 · Enrollment closed in Phase 1 MCL study due to strategic prioritizationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $35 (+317% upside) · 6 analysts
- 2026-03-23HC Wainwright & Co.Buy
- 2026-03-13GuggenheimBuy
- 2026-01-21HC Wainwright & Co.Buy
- 2026-01-06Canaccord GenuityBuy
- 2025-11-07HC Wainwright & Co.Buy
- 2025-10-08GuggenheimBuy
Competitors — CD20
Recent news
- 2026-07-21Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference - Caledonian Record
- 2026-07-21Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference - Yahoo Finance
- 2026-07-21Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference - Business Wire
- 2026-07-21Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference - FinancialContent
- 2026-07-11Price to earnings forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
- 2026-07-03Adicet Bio (ACET) Stock Analysis Report | Financials & Insights - Benzinga España
- 2026-07-01Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
- 2026-06-26ACET Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.